New Two-Drug attack on Tough-to-Treat lung cancer

NCT ID NCT06295432

Recruiting now Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a combination of two new drugs, DZD9008 and AZD4205, is safe and effective for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called an EGFR mutation. It is for patients whose cancer has continued to grow despite receiving standard treatments. The main goals are to see if the drug combination is safe and if it can shrink or control the tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Guangdong Provincial People'S Hospital
RECRUITING

Guangzhou, Guangdong, 510000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Henan Cancer Hospital
RECRUITING

Zhengzhou, China
The First Affiliated Hospital of Xi'an Jiaotong University
COMPLETED

Xi'an, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
COMPLETED

Wuhan, China

Conditions

Explore the condition pages connected to this study.

NON-SMALL-CELL LUNG CANCER